"Omics" Technologies and the Immune System (a) , (b).
Recent advances in genomics-based identification of gene families and gene polymorphisms associated with immune system dysfunction have answered basic questions in immunology and have begun to move forward our understanding of immune-related disease processes. In toxicology, "omic" technologies have the potential to replace or supplement current immunotoxicological screening procedures, to provide insight into potential mode or mechanisms of action, and to provide data suitable for risk assessment. The application of omic technologies to the study of the immune system also has great potential to appreciably impact the diagnosis and treatment of immune-related diseases. This review focuses on the use of omic technologies in immunopharmacology and immunotoxicology, specifically considering the potential for these technologies to impact chemical hazard identification, risk characterization and risk assessment, and the development and application of novel therapeutics. The state of the science of omics technologies and the immune system is addressed in terms of a continuum of understanding of how omics technologies can and cannot yet be applied in the various aspects of immunopharmacology and immunotoxicology. Additionally, information gaps are identified that, once addressed, will move each area further down the continuum of understanding.
Burns-Naas
Leigh Ann
LA
Worldwide Safety Sciences, Pfizer Global Research and Development, San Diego, CA, 92121, USA.
Dearman
Rebecca J
RJ
Germolec
Dori R
DR
Kaminski
Norbert E
NE
Kimber
Ian
I
Ladics
Gregory S
GS
Luebke
Robert W
RW
Pfau
Jean C
JC
Pruett
Stephen B
SB